A. D. Beadell Investment Counsel Inc. Raises Position in Pfizer Inc. (NYSE:PFE)

A. D. Beadell Investment Counsel Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 7.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 47,211 shares of the biopharmaceutical company’s stock after purchasing an additional 3,375 shares during the period. A. D. Beadell Investment Counsel Inc.’s holdings in Pfizer were worth $1,252,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Trecaso Financial Group LLC boosted its stake in Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 350 shares during the last quarter. Washington Trust Advisors Inc. lifted its holdings in shares of Pfizer by 0.7% during the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after purchasing an additional 360 shares in the last quarter. Cullen Investment Group LTD. boosted its position in shares of Pfizer by 0.9% during the third quarter. Cullen Investment Group LTD. now owns 42,677 shares of the biopharmaceutical company’s stock valued at $1,235,000 after buying an additional 377 shares during the last quarter. MidWestOne Financial Group Inc. increased its holdings in Pfizer by 1.5% in the 2nd quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock worth $742,000 after buying an additional 386 shares in the last quarter. Finally, Western Pacific Wealth Management LP raised its position in Pfizer by 10.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 386 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Wolfe Research assumed coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Price Performance

NYSE:PFE traded up $0.09 during trading hours on Friday, hitting $26.95. 12,722,184 shares of the stock traded hands, compared to its average volume of 32,126,992. The company has a market cap of $152.73 billion, a price-to-earnings ratio of 36.42, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $26.21 and a 200 day moving average price of $28.05. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business posted ($0.17) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.38%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is currently 232.43%.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.